Deucravacitinib as a Novel JAK Inhibitor in the Treatment of Autoimmune Disorders

Autoimmune disorders are chronic conditions caused by an overactive immune response against the body’s own tissues, often leading to significant morbidity. The Janus kinase (JAK) pathway plays a crucial role in immune system regulation, making JAK inhibitors an essential class of drugs in managing these diseases. Deucravacitinib, a novel JAK inhibitor specifically targeting the tyrosine kinase 2 (TYK2) enzyme, offers a more selective approach to modulating immune responses. This study aims to evaluate the efficacy, safety, and mechanism of Deucravacitinib compared to conventional JAK inhibitors such as Tofacitinib and Baricitinib. The diseases under investigation include psoriasis, lupus, and rheumatoid arthritis. The research methodology involves an extensive literature review, meta-analysis of clinical trial data, and statistical comparisons of efficacy and adverse effects. Data sources include peer-reviewed journal articles, clinical trial reports, and patient case studies. Results indicate that Deucravacitinib demonstrates a superior efficacy profile with a reduced incidence of severe adverse effects compared to its predecessors. Clinical trials show promising outcomes in managing autoimmune conditions, particularly in reducing inflammation markers and enhancing patient quality of life. However, long-term studies are necessary to establish its sustained effectiveness and safety profile. In conclusion, Deucravacitinib represents a significant advancement in autoimmune disorder treatment by offering a targeted therapeutic strategy with potentially fewer side effects. Future research should focus on long-term patient monitoring and the drug’s efficacy across a broader spectrum of autoimmune conditions. Keywords: Deucravacitinib, Inhibitor, Autoimmune Disorders, Automation.